{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:59:27Z","timestamp":1780361967039,"version":"3.54.1"},"reference-count":42,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81730078"],"award-info":[{"award-number":["81730078"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2021-1-I2M-018"],"award-info":[{"award-number":["2021-1-I2M-018"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["81730078"],"award-info":[{"award-number":["81730078"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2021-1-I2M-018"],"award-info":[{"award-number":["2021-1-I2M-018"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Aberrantly activated mechanistic target of rapamycin (mTOR) signaling pathway stimulates translation initiation\/protein synthesis and eventually causes tumors. Targeting these processes thus holds potential for treating mTOR-associated diseases. We tested the potential of eFT226, a sequence-selective inhibitor of eIF4A-mediated translation, in the treatment of mTOR hyperactive cells caused by the deletion of tuberous sclerosis complex 1\/2 (TSC1\/2) or phosphatase and TENsin homology (PTEN). eFT226 preferentially inhibited the proliferation of Tsc2- and Pten-deficient cells by inducing necroptosis and G2\/M phase arrest. In addition, eFT226 blocked the development of TSC2-deficient tumors. The translation initiation inhibitor is thus a promising regimen for the treatment of hyperactive mTOR-mediated tumors.<\/jats:p>","DOI":"10.3390\/ijms23136932","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T21:31:06Z","timestamp":1655933466000},"page":"6932","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["eIF4A1 Inhibitor Suppresses Hyperactive mTOR-Associated Tumors by Inducing Necroptosis and G2\/M Arrest"],"prefix":"10.3390","volume":"23","author":[{"given":"Luyang","family":"Han","sequence":"first","affiliation":[{"name":"State Key Laboratory of Medical Molecular Biology, Department of Physiology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing 100005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Wu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Medical Molecular Biology, Department of Physiology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing 100005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangming","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Medical Molecular Biology, Department of Physiology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing 100005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6291-1027","authenticated-orcid":false,"given":"Hongbing","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Medical Molecular Biology, Department of Physiology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing 100005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/hmg\/11.5.525","article-title":"A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells","volume":"11","author":"Kwiatkowski","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1056\/NEJMicm1910478","article-title":"The Cowden Syndrome","volume":"382","author":"Moliere","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1146\/annurev-pathol-020117-043609","article-title":"Molecular Genetics of Endometrial Carcinoma","volume":"14","author":"Bell","year":"2019","journal-title":"Annu. Rev. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2021.07.011","article-title":"Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations","volume":"123","author":"Northrup","year":"2021","journal-title":"Pediatr. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.tranon.2016.08.009","article-title":"Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma","volume":"9","author":"Cho","year":"2016","journal-title":"Transl. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1126\/science.1226344","article-title":"Genome sequencing identifies a basis for everolimus sensitivity","volume":"338","author":"Iyer","year":"2012","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1016\/j.ejso.2021.04.001","article-title":"Sirolimus-based immunosuppression improves the prognosis of liver Transplantation Recipients with low TSC1\/2 expression in hepatocellular carcinoma beyond the Milan Criteria","volume":"47","author":"Ye","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2015.02.009","article-title":"PTEN: A yin-yang master regulator protein in health and disease","volume":"77\u201378","author":"Pulido","year":"2015","journal-title":"Methods"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMra055323","article-title":"The tuberous sclerosis complex","volume":"355","author":"Crino","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41568-021-00380-y","article-title":"The plasticity of mRNA translation during cancer progression and therapy resistance","volume":"21","author":"Fabbri","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc1819","article-title":"Beyond PTEN mutations: The PI3K pathway as an integrator of multiple inputs during tumorigenesis","volume":"6","author":"Cully","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1158\/1535-7163.MCT-14-0768","article-title":"Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus","volume":"14","author":"Huynh","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1158\/1078-0432.CCR-19-0471","article-title":"Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study","volume":"26","author":"Soliman","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.jid.2021.02.754","article-title":"Long-Term Effects of Sirolimus on Human Skin TSC2-Null FibroblastLike Cells","volume":"141","author":"Cai","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.1188\/11.CJON.E83-E89","article-title":"Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors","volume":"15","author":"Pilotte","year":"2011","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/TP.0b013e3182551021","article-title":"Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: A critical review of the literature","volume":"94","author":"Nashan","year":"2012","journal-title":"Transplantation"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.2337\/db09-1324","article-title":"Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue","volume":"59","author":"Houde","year":"2010","journal-title":"Diabetes"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd4505","article-title":"Targeting the translation machinery in cancer","volume":"14","author":"Bhat","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"10242","DOI":"10.1039\/D1SC02143E","article-title":"Cellular delivery of dinucleotides by conjugation with small molecules: Targeting translation initiation for anticancer applications","volume":"12","author":"Kleczewska","year":"2021","journal-title":"Chem. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jid.2020.08.021","article-title":"5\u2032-CapDependent Translation as a Potent Therapeutic Target for Lethal Human Squamous Cell Carcinoma","volume":"141","author":"Srivastava","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.1021\/acs.jmedchem.0c00182","article-title":"Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase","volume":"63","author":"Ernst","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cell.2009.01.014","article-title":"Topology and regulation of the human eIF4A\/4G\/4H helicase complex in translation initiation","volume":"136","author":"Marintchev","year":"2009","journal-title":"Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0973","article-title":"Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A","volume":"20","author":"Thompson","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1172\/JCI200317222","article-title":"Loss of Tsc1\/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR","volume":"112","author":"Zhang","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1172\/JCI28984","article-title":"PDGFRs are critical for PI3K\/Akt activation and negatively regulated by mTOR","volume":"117","author":"Zhang","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1172\/JCI37964","article-title":"Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3\/p63\/Jagged\/Notch cascade","volume":"120","author":"Ma","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/gcc.20118","article-title":"Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models","volume":"42","author":"Lee","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1073\/pnas.1014769108","article-title":"Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth","volume":"108","author":"Sun","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1038\/s41418-019-0274-0","article-title":"mTOR-dependent upregulation of xCT blocks melanin synthesis and promotes tumorigenesis","volume":"26","author":"Li","year":"2019","journal-title":"Cell Death Differ."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41375-019-0503-z","article-title":"Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas","volume":"34","author":"Zhang","year":"2020","journal-title":"Leukemia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2014-07-589689","article-title":"Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase","volume":"124","author":"Steinhardt","year":"2014","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"14329","DOI":"10.1038\/ncomms14329","article-title":"RIP1 autophosphorylation is promoted by mitochondrial ROS and is essential for RIP3 recruitment into necrosome","volume":"8","author":"Zhang","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nri3743","article-title":"Regulated cell death and inflammation: An auto-amplification loop causes organ failur","volume":"14","author":"Linkermann","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1056\/NEJMe0707153","article-title":"Efficacy of sirolimus in treating tuberous sclerosis and lymphangioleiomyomatosis","volume":"358","author":"Paul","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_37","first-page":"2651","article-title":"Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model","volume":"118","author":"Bordeleau","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1021\/cb400158t","article-title":"Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex","volume":"8","author":"Sadlish","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1038\/s41418-019-0298-5","article-title":"Cell cycle arrest in mitosis promotes interferon-induced necroptosis","volume":"26","author":"Frank","year":"2019","journal-title":"Cell Death Differ."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"766298","DOI":"10.3389\/fonc.2021.766298","article-title":"Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors","volume":"11","author":"Young","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1128\/MCB.24.1.200-216.2004","article-title":"mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1\/eukaryotic translation initiation factor 4E","volume":"24","author":"Fingar","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"ref_42","first-page":"1913","article-title":"CDK inhibitors in cancer therapy, an overview of recent development","volume":"11","author":"Zhang","year":"2021","journal-title":"Am. J. Cancer Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/13\/6932\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:37:40Z","timestamp":1760139460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/13\/6932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":42,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["ijms23136932"],"URL":"https:\/\/doi.org\/10.3390\/ijms23136932","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,22]]}}}